NICE Backing For Procolaran In CHF May Prove Lucrative For Servier
This article was originally published in The Pink Sheet Daily
If NICE’s backing for Servier’s heart drug Procolaran does spread across Europe, then the resulting returns may offset some of financial pain the French group is set to feel in coming years.
You may also be interested in...
Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.
The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.
Proposal would also shield French regulatory agency that approved the diabetes drug from victims' lawsuits.